Elsevier

The Lancet

Volume 337, Issue 8743, 23 March 1991, Pages 690-694
The Lancet

ORIGINAL ARTICLES
Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects

https://doi.org/10.1016/0140-6736(91)90277-VGet rights and content

Abstract

The effects of a highly selective leukotriene D4 receptor antagonist, ICI 204.219, on allergen-induced bronchoconstriction and changes in airway reactivity were evaluated in a double-blind, placebo-controlled, crossover trial. Ten atopic subjects were selected for the study on the basis of an immediate fall in forced expiratory volume in 1 s (FEV1) of at least 15% and a least a doubling dose fall in their PC20-histamine (the concentration of histamine needed to reduce FEV1 by 20%) after antigen challenge. Baseline PC20-histamine was determined before the ingestion of a single oral 40 mg dose of ICI 204.219 or matched placebo. 2 h later subjects were challenged with aerosolised allergen; FEV1 was measured for the next 6 h then PC20-histamine was remeasured. Two subjects did not complete the study for reasons not related to the trial medication. ICI 204.219 significantly attentuated the early and late phase bronchoconstriction to inhaled allergen (mean treatment difference in area under the FEV1-time curves 2529 [95% Cl 1085-3972] Δ%FEV1.min; p<0·005: and 3537 [528-6545] Δ%FEV1.min; p < 0·03) and suppressed the allergen-induced increase in non-specific bronchial reactivity (mean treatment difference 1·03 [0·34-1·71] doubling dilutions of histamine; p<0·01). These findings suggest that ICI 204.219 may be a disease-modifying agent in asthma. Further studies are under way to evaluate its clinical efficacy.

References (33)

  • B. Samuelsson

    Leukotrienes: mediators of immediate hypersenitivity reactions and inflammation

    Science

    (1983)
  • Jw Weiss et al.

    Airway constriction in normal humans produced by inhalation of leukotriene D: potency, time course and effect of aspirin therapy

    JAMA

    (1983)
  • Gw Taylor et al.

    Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis

    Lancet

    (1989)
  • P. Diaz et al.

    Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late phase asthmatic reactions

    Am Rev Respir Dis

    (1989)
  • Ps Creticos et al.

    Peptide leukotriene release in patients sensitive to ragweed

    N Engl J Med

    (1984)
  • TH. Lee

    Pharmacological modulation of leukotriene and platelet activating factor biosynthesis and activities by alternative dietary fatty adds

    Clin Exp Allergy

    (1989)
  • Cited by (394)

    • Proinflammatory Pathways in the Pathogenesis of Asthma

      2019, Clinics in Chest Medicine
      Citation Excerpt :

      Most of the clinical trials examining the therapeutic effect of LTs in asthma and allergic diseases have been in this class of medications and confirmed that cysteinyl LTs contributed a major portion of the bronchospasm that resulted from allergen challenge. Administration of the cysLT1 antagonist zafirlukast before allergen challenge inhibited immediate-phase bronchospasm by approximately 80% and reduced the late phase by 50%.175,176 CysLT1 antagonists and 5-LO inhibitors blunted the influx of airway inflammatory cells after segmental allergen challenge.177,178

    • Mast cells in airway diseases and interstitial lung disease

      2016, European Journal of Pharmacology
      Citation Excerpt :

      Mast cell-derived mediators induce the classical features of the early asthmatic reaction in vivo, inducing bronchoconstriction, mucus secretion and mucosal oedema (for reviews see Bradding and Cruse (2008), Bradding et al. (2006), Brightling et al. (2003a) and Moiseeva and Bradding (2011)). For example, several studies have identified an increase in histamine, prostaglandin D2 (PGD2) and leukotriene C4 (LTC4) in the BAL fluid of asthma subjects following bronchial allergen challenge (Casale et al., 1987; Liu et al., 1991; Murray et al., 1986; Sedgwick et al., 1991; Wenzel et al., 1988, 1990, 1991) and that the early asthmatic reaction is significantly alleviated with the administration of potent selective inhibitors of histamine, LTC4 and to a lesser extent PGD2 (Beasley et al., 1987; Curzen et al., 1987; Findlay et al., 1992; Rafferty et al., 1987; Taylor et al., 1991). These mediators are most likely derived from mast cells in the bronchial mucosa because histamine, PGD2 and LTC4 are all released from human lung mast cells in vitro with remarkably similar kinetics to the allergen challenge studies (Schleimer et al., 1986).

    • Antileukotriene Therapy in Asthma

      2014, Middleton's Allergy: Principles and Practice: Eighth Edition
    • Therapeutic strategies to reduce asthma exacerbations

      2011, Journal of Allergy and Clinical Immunology
    View all citing articles on Scopus
    View full text